Genmab upgrades financial guidance again

Sales of Darzalex, which is a bone marrow cancer drug, are significantly exceeding expectations, Genmab reports in a stock exchange notification.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Horizon's Genmab drug gets blockbuster status
For subscribers
Analysts say Darzalex sales prognosis could be too cautious
For subscribers